^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | BPI-15086 (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study
Published date:
05/06/2022
Excerpt:
...study included patients...with histologically or cytologically confirmed locally advanced or metastatic T790M+ NSCLC…The ORR and DCR were 17.7% [95% confidence interval (CI) 3.8% to 43.4%] and 47.1% (95% CI 23.0% to 72.2%), respectively….BPI-15086 is a safe and tolerable third-generation EGFR-TKI with a rationale for further clinical studies.
DOI:
https://doi.org/10.1016/j.esmoop.2022.100473
Trial ID:
